Trials / Completed
CompletedNCT03491371
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
The Effectivity and Toxicity of Methylsulfonic Apatinib for Extensively Pre-treated Advanced Sarcoma: a Multicentric Retrospective Study in China
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced sarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of three Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated sarcoma.
Detailed description
The investigators retrospectively analysed files of patients with advanced sarcoma not amenable to curative treatment, who were receiving an apatinib-containing regimen between June 1, 2015 and December 1, 2016. Fifty-six patients were included: 22 osteosarcoma, 10 Ewing's sarcoma, 3 chondrosarcoma and 21 soft tissue sarcoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylsulfonic apatinib | Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2. |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2016-12-31
- Completion
- 2017-02-01
- First posted
- 2018-04-09
- Last updated
- 2018-04-10
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03491371. Inclusion in this directory is not an endorsement.